Furthermore, although TMB and PD‐L1 have served as established biomarkers for patient selection in NSCLC,37, 38 specific markers for direct individualized therapy are currently lacking in patients with ES‐SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.